Imlunestrant
| Clinical data | |
|---|---|
| Pronunciation | /ˌɪmlʊˈnɛstrənt/ IM-luu-NES-trənt |
| Trade names | Inluriyo |
| Other names | LY3484356, LY-3484356 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a625104 |
| License data |
|
| Routes of administration | By mouth |
| Drug class | Estrogen receptor antagonist |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII |
|
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C29H24F4N2O3 |
| Molar mass | 524.516 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Imlunestrant, sold under the brand name Inluriyo, is an anti-cancer medication used for the treatment of breast cancer. It is an estrogen receptor antagonist. It is used as the salt, imlunestrant tosylate. It is taken by mouth. It was developed by Eli Lilly and Company.
The most common adverse events and laboratory abnormalities include decreased hemoglobin, musculoskeletal pain, decreased calcium, decreased neutrophils, increased AST, fatigue, diarrhea, increased ALT, increased triglycerides, nausea, decreased platelets, constipation, increased cholesterol, and abdominal pain.
Imlunestrant was approved for medical use in the United States in September 2025, and in the European Union in January 2026.
Category:
- Drugs not assigned an ATC code